ASSESSING ANTI-TNF TROUGH LEVELS AND ITS APPLICABILITY IN DAILY PRACTICE IN SPONDYLOARTHRITIS PATIENTS

Objective. The purpose of the present study was to assess the relevance of therapeutic drug monitoring in spondyloarthritis patients, by determining drug serum levels and anti-drug antibodies and estimating cut-off values for three TNF inhibitors. Methods. Over one year, we enrolled 100 patients w...

Full description

Bibliographic Details
Main Authors: Claudia Deaconu, Daniela Opris, Ruxandra Ionescu
Format: Article
Language:English
Published: Amaltea Medical Publishing House 2016-09-01
Series:Romanian Journal of Rheumatology
Subjects:
Online Access:https://rjr.com.ro/articles/2016.3/RJR_2016_3_Art-05.pdf
id doaj-3fefa38cb0c241f4ba7f48c1587dd490
record_format Article
spelling doaj-3fefa38cb0c241f4ba7f48c1587dd4902021-09-08T09:24:31ZengAmaltea Medical Publishing HouseRomanian Journal of Rheumatology1843-07912069-60862016-09-0125312713510.37897/RJR.2016.3.5ASSESSING ANTI-TNF TROUGH LEVELS AND ITS APPLICABILITY IN DAILY PRACTICE IN SPONDYLOARTHRITIS PATIENTSClaudia Deaconu0Daniela Opris1Ruxandra Ionescu2Department of Rheumatology and Internal Medicine, Sfanta Maria Clinical Hospital, BucharestDepartment of Rheumatology and Internal Medicine, Sfanta Maria Clinical Hospital, Bucharest; Carol Davila University of Medicine and Pharmacy, BucharestDepartment of Rheumatology and Internal Medicine, Sfanta Maria Clinical Hospital, Bucharest; Carol Davila University of Medicine and Pharmacy, BucharestObjective. The purpose of the present study was to assess the relevance of therapeutic drug monitoring in spondyloarthritis patients, by determining drug serum levels and anti-drug antibodies and estimating cut-off values for three TNF inhibitors. Methods. Over one year, we enrolled 100 patients with SpA, under consequent treatment with adalimumab (ADL), etanercept (ETA) or infliximab (IFX). Demographic, clinical (BASDAI, ASDAS) and laboratory (ESR, CRP) data was collected together with drug serum level and anti-drug antibodies using the ELISA technique. The statistical analysis was performed using the SPSS software, version 20.0 with the aid of Student t-test, Spearman and Pearson tests. Results. Out of the study cohort, 35% were on ADL, 33% on IFX, and 32% under ETA treatment. Undetectable drug levels correlated to the presence of anti-drug antibodies and to disease activity scores. There were no identified anti-ETA antibodies. For this study lot trough levels are estimated between 2 and 4 μg/mL for an ASDAS-CRP under 2.1. Conclusion. Serum drug level measurement and anti-drug antibody detection can be used as a completion to a clinician’s tools in assessing disease activity, leading to an optimal and personalized manner of patient management.https://rjr.com.ro/articles/2016.3/RJR_2016_3_Art-05.pdfspondyloarthritisanti-tnf therapydrug serum levelthrough levelpersonalized medicine
collection DOAJ
language English
format Article
sources DOAJ
author Claudia Deaconu
Daniela Opris
Ruxandra Ionescu
spellingShingle Claudia Deaconu
Daniela Opris
Ruxandra Ionescu
ASSESSING ANTI-TNF TROUGH LEVELS AND ITS APPLICABILITY IN DAILY PRACTICE IN SPONDYLOARTHRITIS PATIENTS
Romanian Journal of Rheumatology
spondyloarthritis
anti-tnf therapy
drug serum level
through level
personalized medicine
author_facet Claudia Deaconu
Daniela Opris
Ruxandra Ionescu
author_sort Claudia Deaconu
title ASSESSING ANTI-TNF TROUGH LEVELS AND ITS APPLICABILITY IN DAILY PRACTICE IN SPONDYLOARTHRITIS PATIENTS
title_short ASSESSING ANTI-TNF TROUGH LEVELS AND ITS APPLICABILITY IN DAILY PRACTICE IN SPONDYLOARTHRITIS PATIENTS
title_full ASSESSING ANTI-TNF TROUGH LEVELS AND ITS APPLICABILITY IN DAILY PRACTICE IN SPONDYLOARTHRITIS PATIENTS
title_fullStr ASSESSING ANTI-TNF TROUGH LEVELS AND ITS APPLICABILITY IN DAILY PRACTICE IN SPONDYLOARTHRITIS PATIENTS
title_full_unstemmed ASSESSING ANTI-TNF TROUGH LEVELS AND ITS APPLICABILITY IN DAILY PRACTICE IN SPONDYLOARTHRITIS PATIENTS
title_sort assessing anti-tnf trough levels and its applicability in daily practice in spondyloarthritis patients
publisher Amaltea Medical Publishing House
series Romanian Journal of Rheumatology
issn 1843-0791
2069-6086
publishDate 2016-09-01
description Objective. The purpose of the present study was to assess the relevance of therapeutic drug monitoring in spondyloarthritis patients, by determining drug serum levels and anti-drug antibodies and estimating cut-off values for three TNF inhibitors. Methods. Over one year, we enrolled 100 patients with SpA, under consequent treatment with adalimumab (ADL), etanercept (ETA) or infliximab (IFX). Demographic, clinical (BASDAI, ASDAS) and laboratory (ESR, CRP) data was collected together with drug serum level and anti-drug antibodies using the ELISA technique. The statistical analysis was performed using the SPSS software, version 20.0 with the aid of Student t-test, Spearman and Pearson tests. Results. Out of the study cohort, 35% were on ADL, 33% on IFX, and 32% under ETA treatment. Undetectable drug levels correlated to the presence of anti-drug antibodies and to disease activity scores. There were no identified anti-ETA antibodies. For this study lot trough levels are estimated between 2 and 4 μg/mL for an ASDAS-CRP under 2.1. Conclusion. Serum drug level measurement and anti-drug antibody detection can be used as a completion to a clinician’s tools in assessing disease activity, leading to an optimal and personalized manner of patient management.
topic spondyloarthritis
anti-tnf therapy
drug serum level
through level
personalized medicine
url https://rjr.com.ro/articles/2016.3/RJR_2016_3_Art-05.pdf
work_keys_str_mv AT claudiadeaconu assessingantitnftroughlevelsanditsapplicabilityindailypracticeinspondyloarthritispatients
AT danielaopris assessingantitnftroughlevelsanditsapplicabilityindailypracticeinspondyloarthritispatients
AT ruxandraionescu assessingantitnftroughlevelsanditsapplicabilityindailypracticeinspondyloarthritispatients
_version_ 1717762461232267264